Cargando…
Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non‐compaction cardiomyopathy (NCCM) individuals. The aim of this article is to report a case of a patient with NCCM initially...
Autores principales: | Bonatto, Marcely Gimenes, Albanez, Rodrigo, Salemi, Vera Maria Cury, Moura, Lídia Zytynski |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261575/ https://www.ncbi.nlm.nih.gov/pubmed/32304161 http://dx.doi.org/10.1002/ehf2.12713 |
Ejemplares similares
-
A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy
por: De Vecchis, Renato, et al.
Publicado: (2020) -
Use of sacubitril/valsartan in Marfan syndrome–related cardiomyopathy: The first case report
por: Spoto, Silvia, et al.
Publicado: (2019) -
Successful treatment of doxorubicin-induced cardiomyopathy with low-dose sacubitril/valsartan: a case report
por: Bell, Elisabeth, et al.
Publicado: (2022) -
Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021) -
Recurrent hypotension induced by sacubitril/valsartan in cardiomyopathy secondary to Duchenne muscular dystrophy: A case report
por: Li, Jia-Min, et al.
Publicado: (2019)